Jeffrey Albers Net Worth & Insider Trades
Jeffrey Albers Blueprint Medicines Corp
What is Jeffrey Albers's Net Worth?
The current estimated net worth of Blueprint Medicines Corp's Jeffrey Albers is estimated to be about $50.3M . Jeffrey Albers owns about 173,450 units of Blueprint Medicines Corp common stock. In the last 8 years at Blueprint Medicines Corp, Jeffrey Albers has sold an estimated value of $44.95M worth.
What is Jeffrey Albers's Past Insider Trading?
Jeffrey Albers's largest purchase order was 30,000 units , worth over $351.75K on November 17, 2021. Jeffrey Albers's largest sale order was 30,000 units , worth over $3.44M on November 17, 2021. In total, Jeffrey Albers has made about 48 transactions over 8 years of their time at Blueprint Medicines Corp. Jeffrey Albers usually trades in March, with the busiest year in 2022 and 2020. The most recent transaction was a sale order of 9,793 units , worth over $447.27K on March 8, 2023.
Jeffrey Albers
Date Range: All Time
Ticker
|
Type
|
Value
|
Price per Share
|
Shares
|
Filing Date
| ||
|---|---|---|---|---|---|---|---|
| No matching records found | |||||||
What was Jeffrey Albers's Salary in 2020?
As an executive member of Blueprint Medicines Corp, Jeffrey Albers has a total base salary of $645,000 . Jeffrey Albers received compensation valued at about $6,344,667 in 2020.
What is Jeffrey Albers's' Mailing Address?
- Mailing address is Blueprint Medicines Corp. 215 First Street, Suite 340/350 Cambridge MA 02142 MA
Blueprint Medicines Corp Executive Compensation
Name |
Year
|
Salary
|
Total
|
|---|---|---|---|
| Jeffrey W. Albers | 2020 | $645,000 | $6,344,667 |
| Jeffrey W. Albers | 2019 | $590,000 | $9,362,371 |
| Jeffrey W. Albers | 2018 | $541,144 | $9,740,799 |
| Michael Landsittel | 2020 | $379,575 | $2,014,974 |
| Michael Landsittel | 2019 | $345,000 | $1,958,720 |
| Michael Landsittel | 2018 | $281,678 | $1,740,610 |
| Fouad Namouni, M.D. | 2020 | $186,154 | $6,668,732 |
| Fouad Namouni, M.D. | 2019 | - | - |
| Fouad Namouni, M.D. | 2018 | - | - |
| Kathryn Haviland | 2020 | $460,944 | $2,363,556 |
| Kathryn Haviland | 2019 | $431,830 | $3,090,423 |
| Kathryn Haviland | 2018 | $392,589 | $2,601,762 |
| Tracey L. McCain, Esq. | 2020 | $453,301 | $2,346,428 |
| Tracey L. McCain, Esq. | 2019 | $437,972 | $2,900,568 |
| Tracey L. McCain, Esq. | 2018 | $425,216 | $2,647,962 |
| No matching records found | |||
Source: https://www.sec.gov/Archives/edgar/data/1597264/000155837021004557/tmb-20210602xdef14a.htm
What are Blueprint Medicines Corp's Past Insider Trades?
Blueprint Medicines Corp's most recent insider trade came on March 8, 2023 by Christopher Murray who sold 1,875 units worth $85.64K . In the last 8 years, insiders at Blueprint Medicines Corp have sold an estimated value of $175.48M and bought an estimated value of $17.63M worth of shares. Insider trading is most common in March, with the busiest year in 2020. The most active traders at the company are Jeffrey Albers, Kate Haviland, CHIEF EXECUTIVE OFFICER, and Ariel Hurley, PRINCIPAL ACCOUNTING OFFICER .
Blueprint Medicines Corp Insider Trades
Date Range: All Time
Insider Names
|
Type
|
Value
|
Price per Share
|
Shares
|
Filing Date
| ||
|---|---|---|---|---|---|---|---|
| No matching records found | |||||||